Scil Technology has a pipeline of six therapeutic candidates targeting at either dental or orthopaedic indications. Each of these candidates combines a synthetic implant or biomaterial with one of the three bone or cartilage growth factors, rhGDF-5, rhBMP variant or rhCD-RAP, and incorporates Scil Technology’s proprietary protein coating technology to ensure homogeneity and stability of the growth factor on the biomaterial.

[+] larger view (PDF)

The lead project, MD05, a synthetic bone augmentation material for dental implantology and bone defects resulting from severe periodontal disease, has completed clinical Phase II development for dental implantology. A second clinical Phase II development on MD05 addressing the induction of dental tissue regeneration for the treatment of periodontal disease has been initiated.  This product candidate has demonstrated superior efficacy in various relevant preclinical models compared to the gold standard treatment (autologous bone) as well as currently marketed competitor products. Of the two other dental projects, a growth factor activated dental implant, MD06, is in preclinical stage and an adhesive paste containing a growth factor for restoration of periodontal attachment apparatus, MD08, is in advanced preclinical proof-of-concept studies.

The first project in the orthopaedic field is ST01.  It is a fully synthetic bone substrate material aiming for the treatment of lumbar, thoracic and cervical fusion and related procedures.  Its superiority has been demonstrated in a preclinical proof-of-concept spinal fusion animal model.  The company is also developing an in situ forming scaffold targeted at fracture repair.

The project portfolio is further augmented by two product candidates for cartilage repair, ST03 and ST04, which are based on a highly specific cartilage growth factor, rhCD-RAP. These projects target repairing damaged cartilage caused by injuries related to accidents (sports, motor vehicle) or age-related degenerative cartilage lesions.  Both projects have recently been successfully partnered with Pfizer Inc.

All projects are protected by Scil’s patents and patent applications or by licensed patent rights.